
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.

Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.

Cancer diagnoses among civilians exposed to 9/11 dust keep rising, with strained health programs struggling to meet growing needs.

The data support GPRC5D-directed CAR T-cell therapy as a potential option following prior BCMA-targeted treatment.

The FDA expanded the accelerated approval of sevabertinib to include treatment-naive adults with locally advanced or metastatic nonsquamous NSCLC harboring HER2 tyrosine kinase domain-activating mutations.

The phase 3 DeLLphi-305 trial found that the first-line maintenance therapy improved overall survival in extensive-stage small cell lung cancer (ES-SCLC) compared with durvalumab alone.

Camizestrant is the first cancer therapy guided by a ctDNA resistance mutation detected before imaging shows disease progression.

Preclinical research identifies tumor-secreted PRDX1 as a potential “redox checkpoint” that suppresses T-cell activity and may contribute to resistance to immune checkpoint inhibitors.

A prospective multicenter study found high response rates with first-line obinutuzumab plus bendamustine across several indolent B-cell lymphoma subtypes, although short follow-up and the absence of a comparator limit conclusions about long-term benefit.

An ifosfamide shortage prompts cancer treatment concerns and new importation efforts.

Blood Cancer Awareness Month highlights types of blood cancer and how pharmacists flag multiple myeloma symptoms early, speeding referral and care.

This FAQ describes what oncology pharmacists should know ahead of Gynecologic Cancer Awareness Month in September.

August 2026 brought major oncology advances, including new FDA approvals and pivotal phase 3 data that expanded targeted, immune-based, and personalized treatment strategies.

August 2026 brought first-in-class approvals in multiple myeloma, warm autoimmune hemolytic anemia, and polycythemia vera alongside important findings involving bispecific antibodies, sickle cell pain, and infection risk.

Rusfertide gives adults with polycythemia vera a first-in-class option to cut phlebotomy dependence and control hematocrit.

Tarlatamab targets DLL3 in lung cancer; learn step-up dosing, CRS/ICANS monitoring, and pharmacy tips to keep patients safely on therapy.

Experts gather for a roundtable on the rare, delayed toxicities associated with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Early-phase trial data showed antitumor activity in heavily pretreated metastatic colorectal cancer.

If Heidi Overton is confirmed, the FDA nominee's views on abortion pills, vaccines, and drug review could reshape pharmacists' daily work.

Ivonescimab plus chemotherapy significantly improved overall survival compared with durvalumab plus chemotherapy in patients with previously untreated advanced biliary tract cancer.

Daraxonrasib, an oral RAS inhibitor, was approved for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or when multiagent systemic therapy is not appropriate.

Sunburn and tanning signal DNA damage—learn SPF 30+ sunscreen tips, reapplication, and medication photosensitivity for skin cancer prevention.

The FDA has approved 2 zanidatamab-hrii–based regimens following phase 3 results demonstrating significant improvements in progression-free survival.

The FDA has granted fast track designation to ERAS-0015, an investigational oral pan-RAS molecular glue that has shown early antitumor activity in previously treated KRAS G12X pancreatic ductal adenocarcinoma.

The FDA-granted priority review raises the possibility of an immunotherapy-first approach that could allow some patients to avoid chemotherapy, radiation, and surgery.

The FDA granted fast track designation to safusidenib, an investigational oral IDH1 inhibitor that produced durable responses in a phase 2 study of patients with treatment-naive grade 2 IDH1-mutant glioma.

Cardiomyopathy, hepatitis B, breast cancer, hypertension, and myeloma decisions land in the FDA's final-quarter queue.

Following community reports of more than 400 cancer cases in Keyport and Union Beach, New Jersey officials are expanding environmental sampling near a former landfill.

Decode carcinogens: IARC hazard vs risk, what "possibly" means, and how pharmacists ease aspartame, meat, and phone fears.

Mattew Lei, PharmD, BCOP,breaks down the FDA approval of subcutaneous isatuximab-irfc via the CirCLIQ on-body injector.

Intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival over pembrolizumab alone.